Introduction {#H1-1-ZOI200103}
============

The landscape of chronic liver disease (CLD) in the US is rapidly changing. This condition is currently the fourth leading cause of death among persons aged 45 to 64 years.^[@zoi200103r1]^ With improvements in the management and treatment of viral hepatitis, the burden of liver disease is shifting toward alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD).^[@zoi200103r2],[@zoi200103r3],[@zoi200103r4],[@zoi200103r5]^ A recent US population-based study focusing on cirrhosis-related mortality observed that increasing cirrhosis death rates in the US were largely driven by alcoholic cirrhosis, with the greatest increases seen among young adults aged 25 to 34 years.^[@zoi200103r6]^

Inpatient hospitalization and care are a major contributor to health care resource utilization among patients with CLD.^[@zoi200103r7],[@zoi200103r8],[@zoi200103r9],[@zoi200103r10]^ Few prior studies have used large-scale population-based data sets to evaluate time trends in the total CLD burden and among individual CLD etiologies,^[@zoi200103r4],[@zoi200103r11],[@zoi200103r12]^ cirrhosis, and complications associated with cirrhosis.^[@zoi200103r13]^ Asrani et al^[@zoi200103r14],[@zoi200103r15]^ illustrated trends in the increasing burden of CLD using patient data from hospitalizations in a large and diverse metroplex. Another study^[@zoi200103r4]^ used the National Health and Nutrition Examination Survey database to provide a more generalizable, comprehensive overview of CLD epidemiology in the US. While the inpatient burden remains unknown, these studies highlight the significant clinical impact of CLD. A more thorough understanding of trends in the hospitalization burden of CLD is an important first step in identifying potential areas of focus for public health initiatives and quality improvement programs to ameliorate CLD-related health care resource utilization in the US.

This study specifically aims to comprehensively evaluate the inpatient clinical and economic burden of CLD using a nationally representative sample of CLD-related hospitalizations and further analyze demographic and etiology-specific differences.

Methods {#H1-2-ZOI200103}
=======

This study used deidentified data and was granted exempt status by the Alameda Health System institutional review board. We conducted analysis of these data from June 2019 to October 2019. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.^[@zoi200103r16]^

Data Source {#H2-1-ZOI200103}
-----------

This study evaluated 2012 to 2016 data from the National Inpatient Sample (NIS).^[@zoi200103r17]^ The NIS is the largest all-payer inpatient database of hospital discharges in the US and is maintained as part of the Healthcare Cost and Utilization Project by the Agency for Healthcare Research and Quality. The NIS contains deidentified information regarding each hospitalization, including patient demographic characteristics, admission status, discharge diagnoses, procedures, comorbid conditions, outcomes, and hospital charges. If race and ethnicity were provided in separate data elements, ethnicity took precedence over race in setting the Healthcare Cost and Utilization Project value for race. Participating hospitals are sampled based on characteristics such as size, location (rural vs urban), geographic region, ownership, and teaching status. Starting in 2012, the NIS modified its method of data acquisition to include a systematic sampling of 20% of discharges from all hospitals stratified by hospital, US Census division, ownership status, urban vs rural location, teaching status, and bed size, as well as patient diagnosis-related group and admission month.^[@zoi200103r17]^ In 2015, data elements and data structure for the NIS were changed again.^[@zoi200103r18]^ Trends based on diagnoses or procedures were affected because, starting October 2015, hospital administrative data in the US began using *International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System (ICD-10-CM/PCS)*. In the 2015 NIS, the first 9 months contain *International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)* codes and the last 3 months contain *ICD-10-CM/PCS* codes.^[@zoi200103r19],[@zoi200103r20],[@zoi200103r21]^ The Elixhauser Comorbidity Index software indicators were not available beginning October 1, 2015, because the *ICD-10-CM* version of the software is still under development.^[@zoi200103r18]^

Study Population and Variables {#H2-2-ZOI200103}
------------------------------

The sample included CLD-related hospitalizations of US adults (aged ≥18 years) between January 1, 2012, and December 31, 2016. We defined CLD using a comprehensive review of *ICD-9-CM* codes based on prior published algorithms^[@zoi200103r14],[@zoi200103r15]^ from January 1, 2012, to September 30, 2015, and corresponding *ICD-10-CM* codes starting October 1, 2015 (eFigure and eTable 1 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}). To minimize ascertainment bias, we classified a hospitalization as CLD related if it was associated with (1) a primary discharge diagnosis of CLD or (2) a primary discharge diagnosis of another liver-related cause (eg, cirrhosis) in combination with a secondary diagnosis of CLD (eTable 1 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}).

Among CLD-related hospitalizations, we stratified hospitalizations by 4 main etiologies (alcoholic cirrhosis, hepatitis B virus \[HBV\] infection, hepatitis C virus \[HCV\] infection, and NAFLD), as these etiologies combined account for most of the burden of CLD among hospitalized patients in the US. Adult hospitalizations with alcoholic cirrhosis were identified by first isolating all hospitalizations with cirrhosis listed as a diagnosis (eTable 2 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}). From the cohort with cirrhosis, we excluded patients with autoimmune hepatitis, viral hepatitis, hemochromatosis, only NAFLD-specific codes (*ICD-9:* 571.5, 571.8-9; *ICD-10:* K75.81), primary biliary cholangitis, and primary sclerosing cholangitis listed as a diagnosis (eTable 2 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}). We then defined alcoholic cirrhosis as hospitalizations with ALD or alcohol use disorder in addition to cirrhosis^[@zoi200103r22]^ (eTable 2 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}). Adult hospitalizations with NAFLD were identified by first using *ICD* codes for liver disease without mention of alcohol (*ICD-9:* 571.5, 571.8-9, 567.23, 572.2-4, 456.0-2x, 789.5x; *ICD-10:* I85.xx, K65.2, K72.1x, K72.9x, K74.0-2, K74.6x, K75.8x, K75.9, K76.0, K76.6-9, K77, R18.x) and then excluding patients with chronic liver disease with mention of alcohol or alcohol use disorder (eTable 2 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}), alcoholic cirrhosis, and other etiologies of acute or chronic liver disease^[@zoi200103r8],[@zoi200103r11],[@zoi200103r23]^ (autoimmune hepatitis, Budd-Chiari syndrome, chronic passive congestion of liver, clonorchiasis, disorders of porphyrin and bilirubin metabolism, echinococcus of liver, fascioliasis, Gaucher disease, hemochromatosis, viral hepatitis, lysosomal acid lipase deficiency and other lipoid disorders, opisthorchiasis, other amyloidosis, other deficiencies of circulating enzymes, other disorders of the liver, primary biliary cholangitis, primary sclerosing cholangitis, syphilis of the liver, or Wilson disease) (eTable 2 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}). Patients with alcohol abuse listed as an Elixhauser comorbidity were included in the alcoholic cirrhosis cohort and excluded from the NAFLD cohort for data using *ICD-9-CM* codes.

We additionally evaluated for the presence of hepatocellular carcinoma, cirrhosis, and cirrhosis-related complications, including ascites, esophageal varices, hepatic encephalopathy, and hepatorenal syndrome (eTable 1 and eTable 2 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}).

Outcome Measures {#H2-3-ZOI200103}
----------------

We estimated the number of CLD-related hospitalizations in each study year. We further described demographic (age, sex, race, and insurance), clinical (liver disease etiology; hepatocellular carcinoma; cirrhosis and concurrent presence of 0, 1, or ≥2 cirrhosis-related complications among patients with cirrhosis; and comorbidities), and hospital characteristics (region, bed size, location, and teaching status) of the sample in each study year. Among CLD-related hospitalizations, we examined year-specific in-hospital mortality and hospitalization costs, stratified by demographic and clinical characteristics.

Hospitalization charges as provided within the data set were inflation adjusted to and reported as 2016 US dollars using the Consumer Price Index maintained by the US Department of Labor.^[@zoi200103r24]^ Hospitalization charges may be confounded by payer policies and other factors unrelated to resource utilization. Therefore, hospitalization costs were calculated for each hospitalization using hospital-specific cost to charge ratios developed by the Agency for Healthcare Research and Quality.^[@zoi200103r25]^

Missing Data {#H2-4-ZOI200103}
------------

Hospitalizations with missing data on age and/or sex were excluded. Hospitalizations with missing data on race (4.4%) were coded with a dummy variable to represent the missing data. In all, 0.2% of observations were missing data on insurance status, 0.07% of hospitalizations were missing data on in-hospital mortality, and 2.0% were missing data on costs. Because missingness for each variable with missing observations was 5% or less, and because the study was a cross-sectional analysis of trends, observations with missing data were excluded from the analysis of the respective variable.^[@zoi200103r27],[@zoi200103r28]^

Statistical Analysis {#H2-5-ZOI200103}
--------------------

Data were survey-weighted using individual discharge weights to obtain descriptive statistics and national estimates. We analyzed time trends in the rate of CLD-related hospitalizations, and among CLD-related hospitalizations, we analyzed trends in the prevalence of demographic and clinical characteristics. We further analyzed trends in in-hospital mortality, mean hospitalization costs, and total hospitalization costs; we performed subgroup analyses by demographic and clinical characteristics. Secular trends were assessed after regressing all outcomes on year, modeled as a continuous variable. We used logistic regression for demographic and clinical outcomes and in-hospital mortality and linear regression after log-transforming the outcome for mean hospitalization costs. We used Poisson regression with count variables to test for trend in the rate of CLD-related hospitalizations. Between-group comparisons used Pearson χ^2^ tests for binary and categorical variables.

A 2-tailed *P* \< .05 was considered statistically significant. Statistical analyses were performed using Stata version 14.0 (StataCorp). We followed the research practices recommended when using NIS data.^[@zoi200103r26]^

Results {#H1-3-ZOI200103}
=======

Characteristics of the Study Cohort {#H2-6-ZOI200103}
-----------------------------------

Among 1 016 743 CLD-related hospitalizations from 2012 to 2016, the mean (SD) patient age was 57.4 (14.4) years; 582 197 (57.3%) were male; and 633 082 (62.3%) were white, 138 068 (13.6%) were African American, and 134 662 (13.2%) were Hispanic ([Table 1](#zoi200103t1){ref-type="table"}). The largest proportion of hospitalizations were for patients aged 45 to 64 years (53.0% \[95% CI, 52.8%-53.1%\]). Medicare was the most common insurance type (42.7% \[95% CI, 42.5%-42.9%\]), followed by Medicaid or private insurance. The mean (SD) length of hospitalization was 6.3 (8.0) days. The most common liver disease etiology was HCV (31.6% \[95% CI, 31.3%-31.9%\]). Overall, 538 720 hospitalizations (95% CI, 53.0% \[52.8%-53.2%\]) had cirrhosis, and 25.7% (95% CI, 25.5%-25.8%) had cirrhosis with 1 cirrhosis-related complication present. Hypertension and diabetes were the most prevalent comorbidities ([Table 1](#zoi200103t1){ref-type="table"}).

###### Trends in the Clinical and Demographic Characteristics of the Study Cohort

  Characteristic                                                     Hospitalizations related to chronic liver disease, weighted % (95% CI)   *P* value for trend                                                                               
  ------------------------------------------------------------------ ------------------------------------------------------------------------ --------------------- ------------------ ------------------ ------------------ ------------------ --------
  Chronic liver disease--related hospitalizations per 100 000, No.   3372                                                                     3056                  3214               3380               3459               3757               \<.001
  Age, mean (SD), y                                                  57.4 (14.4)                                                              56.8 (14.2)           57.1 (14.3)        57.3 (14.4)        57.7 (14.5)        57.8 (14.6)        \<.001
  Age, y                                                                                                                                                                                                                                        
  \<25                                                               1.5 (1.5-1.6)                                                            1.6 (1.5-1.6)         1.6 (1.6-1.7)      1.6 (1.5-1.6)      1.5 (1.5-1.6)      1.5 (1.4-1.5)      .02
  25-44                                                              15.7 (15.6-15.8)                                                         15.6 (15.3-15.9)      15.4 (15.1-15.7)   15.6 (15.4-15.9)   15.7 (15.4-16.0)   16.1 (15.8-16.4)   .01
  45-64                                                              53.0 (52.8-53.1)                                                         55.5 (55.1-55.9)      54.4 (54.0-54.8)   53.4 (53.0-53.8)   51.9 (51.5-52.2)   50.3 (49.9-50.6)   \<.001
  ≥65                                                                29.8 (29.6-30.0)                                                         27.4 (26.9-27.9)      28.6 (28.2-29.2)   29.4 (28.9-29.9)   30.9 (30.4-31.4)   32.2 (31.7-32.6)   \<.001
  Sex                                                                                                                                                                                                                                           
  Male                                                               57.3 (57.1-57.4)                                                         57.8 (57.5-58.1)      57.5 (57.2-57.8)   57.2 (56.9-57.7)   56.9 (56.6-57.2)   57.0 (56.7-57.3)   \<.001
  Female                                                             42.7 (42.6-42.9)                                                         42.2 (41.9-42.5)      42.5 (42.2-42.8)   42.8 (42.5-43.1)   43.1 (42.8-43.4)   43.0 (42.7-43.3)   \<.001
  Race                                                                                                                                                                                                                                          
  White                                                              62.3 (61.7-62.8)                                                         61.6 (60.2-63.0)      62.1 (60.7-63.5)   62.6 (61.2-64.0)   62.4 (61.1-63.7)   62.5 (61.2-63.8)   .35
  African American                                                   13.6 (13.3-13.9)                                                         14.1 (13.3-15.0)      13.6 (12.8-14.4)   13.4 (12.7-14.2)   13.4 (12.7-14.2)   13.5 (12.8-14.2)   .26
  Hispanic                                                           13.2 (12.9-13.6)                                                         13.0 (12.0-14.0)      13.1 (12.2-14.2)   13.0 (12.1-14.0)   13.5 (12.5-14.4)   13.6 (12.7-14.6)   .31
  Asian/Pacific Islander                                             2.5 (2.4-2.6)                                                            2.3 (2.1-2.6)         2.5 (2.2-2.8)      2.5 (2.2-2.8)      2.6 (2.4-2.9)      2.6 (2.3-2.8)      .18
  Other                                                              4.1 (3.9-4.3)                                                            4.6 (3.9-5.3)         3.8 (3.4-4.3)      4.1 (3.7-4.5)      3.8 (3.4-4.2)      4.0 (3.6-4.5)      .26
  Missing                                                            4.4 (4.0-4.7)                                                            4.4 (3.7-5.4)         4.9 (4.0-5.9)      4.5 (3.6-5.5)      4.3 (3.5-5.2)      3.8 (3.1-4.8)      .17
  Insurance                                                                                                                                                                                                                                     
  Medicare                                                           42.7 (42.5-42.9)                                                         41.7 (41.1-42.2)      42.3 (41.8-42.8)   42.7 (42.2-43.3)   43.1 (42.6-43.6)   43.6 (43.1-44.1)   \<.001
  Medicaid                                                           23.5 (23.2-23.8)                                                         21.6 (20.9-22.2)      21.3 (20.7-22.0)   24.5 (23.7-25.3)   24.6 (23.9-25.4)   24.9 (24.2-25.7)   \<.001
  Private, including health maintenance organization                 22.4 (22.1-22.6)                                                         22.4 (21.8-23.0)      22.0 (21.4-22.6)   22.5 (21.9-23.2)   22.7 (22.1-23.3)   22.1 (21.6-22.7)   .86
  Self-pay                                                           7.1 (6.9-7.3)                                                            9.1 (8.6-9.5)         8.8 (8.4-9.3)      6.5 (6.1-6.9)      5.8 (5.4-6.2)      5.7 (5.3-6.1)      \<.001
  No charge                                                          0.8 (0.7-0.8)                                                            0.8 (0.7-1.0)         1.2 (1.0-1.4)      0.7 (0.6-0.8)      0.6 (0.5-0.8)      0.6 (0.5-0.7)      \<.001
  Other                                                              3.6 (3.5-3.8)                                                            4.5 (4.2-4.9)         4.4 (4.0-4.7)      3.1 (2.9-3.4)      3.1 (2.9-3.4)      3.1 (2.9-3.4)      \<.001
  Hospital region                                                                                                                                                                                                                               
  Northeast                                                          18.4 (17.8-18.9)                                                         19.3 (17.4-21.4)      18.8 (16.8-20.9)   18.6 (16.7-20.6)   17.6 (15.9-19.6)   17.7 (15.9-19.6)   .20
  Midwest                                                            19.2 (18.7-19.8)                                                         19.7 (17.9-21.7)      19.8 (18.0-21.9)   19.0 (17.2-20.9)   18.8 (17.1-20.6)   18.9 (17.2-20.8)   .42
  South                                                              39.7 (39.1-40.3)                                                         38.8 (36.3-41.3)      39.3 (36.8-41.8)   39.8 (37.4-42.3)   40.1 (37.7-42.5)   40.2 (37.9-42.6)   .40
  West                                                               22.7 (22.2-23.3)                                                         22.2 (20.3-24.2)      22.1 (20.2-24.1)   22.6 (20.7-24.7)   23.5 (21.6-25.6)   23.2 (21.3-25.2)   .33
  Hospital bed size                                                                                                                                                                                                                             
  Small                                                              15.2 (14.8-15.6)                                                         12.5 (11.4-13.8)      12.4 (11.3-13.6)   17.1 (15.8-18.5)   16.5 (15.2-17.8)   17.1 (15.8-18.4)   \<.001
  Medium                                                             27.6 (27.1-28.1)                                                         26.0 (24.1-27.9)      25.9 (24.0-27.9)   28.4 (26.4-30.4)   29.1 (27.2-31.0)   28.2 (26.3-30.1)   .03
  Large                                                              57.2 (56.6-57.8)                                                         61.5 (59.3-63.7)      61.7 (59.4-63.9)   54.6 (52.2-56.9)   54.5 (52.2-56.8)   54.7 (52.4-57.0)   \<.001
  Hospital location and teaching status                                                                                                                                                                                                         
  Rural                                                              8.1 (7.9-8.4)                                                            9.3 (8.4-10.2)        9.3 (8.5-10.3)     7.7 (6.9-8.6)      7.3 (6.6-8.0)      7.2 (6.5-7.9)      \<.001
  Urban, nonteaching                                                 29.3 (28.8-29.8)                                                         35.9 (33.8-38.0)      35.3 (33.2-37.4)   25.3 (23.5-27.1)   25.9 (24.2-27.7)   25.3 (23.6-27.1)   \<.001
  Urban, teaching                                                    62.6 (62.1-63.2)                                                         54.9 (52.5-57.2)      55.4 (53.0-57.8)   67.0 (65.0-69.0)   66.8 (64.8-68.7)   67.5 (65.6-69.4)   \<.001
  Length of stay, mean (SD), d                                       6.3 (8.0)                                                                6.3 (8.2)             6.2 (8.1)          6.4 (8.3)          6.0 (7.2)          6.4 (8.2)          .77
  Alcoholic cirrhosis                                                24.5 (24.3-24.7)                                                         19.4 (19.1-19.8)      19.6 (19.2-19.9)   19.6 (19.3-19.9)   23.9 (23.6-24.2)   37.7 (37.2-38.1)   \<.001
  Hepatitis B virus                                                  4.4 (4.4-4.5)                                                            4.9 (4.7-5.1)         4.8 (4.6-5.0)      4.4 (4.2-4.6)      4.1 (3.9-4.2)      4.1 (3.9-4.3)      \<.001
  Hepatitis C virus                                                  31.6 (31.3-31.9)                                                         35.2 (34.4-35.9)      33.6 (32.9-34.3)   31.9 (31.2-32.5)   30.3 (29.7-30.9)   27.9 (27.3-28.5)   \<.001
  Nonalcoholic fatty liver disease                                   19.8 (19.7-20.0)                                                         18.6 (18.2-19.0)      19.9 (19.5-20.3)   21.4 (21.0-21.8)   21.4 (21.0-21.8)   18.0 (17.6-18.4)   .67
  Hepatocellular carcinoma                                           4.5 (4.4-4.6)                                                            4.7 (4.4-5.0)         4.7 (4.5-5.0)      4.5 (4.3-4.8)      4.4 (4.2-4.6)      4.0 (3.8-4.2)      \<.001
  Cirrhosis                                                          53.0 (52.8-53.2)                                                         51.2 (50.6-51.7)      51.8 (51.3-52.4)   52.0 (51.5-52.5)   53.0 (52.5-53.5)   56.4 (55.9-56.8)   \<.001
  Cirrhosis-related complications, No.                                                                                                                                                                                                          
  0                                                                  14.7 (14.6-14.8)                                                         14.8 (14.5-15.0)      14.8 (14.6-15.0)   14.6 (14.4-14.9)   14.8 (14.6-15.0)   14.5 (14.2-14.7)   .08
  1                                                                  25.7 (25.5-25.8)                                                         24.7 (24.4-25.1)      25.0 (24.7-25.3)   24.8 (24.5-25.1)   25.4 (25.1-25.6)   28.1 (27.8-28.3)   \<.001
  ≥2                                                                 12.6 (12.5-12.8)                                                         11.6 (11.3-12.0)      12.0 (11.7-12.4)   12.6 (12.3-12.9)   12.8 (12.5-13.2)   13.8 (13.5-14.2)   \<.001
  Coronary artery disease                                            14.5 (14.4-14.6)                                                         13.5 (13.2-13.8)      13.8 (13.5-14.1)   13.9 (13.7-14.2)   14.7 (14.5-15.0)   16.0 (15.8-16.3)   \<.001
  Congestive heart failure                                           14.5 (14.4-14.6)                                                         12.9 (12.7-13.2)      13.4 (13.2-13.7)   14.3 (14.0-14.5)   15.1 (14.8-15.3)   16.4 (16.2-16.7)   \<.001
  Chronic kidney disease                                             20.7 (20.5-20.8)                                                         18.6 (18.3-19.0)      19.4 (19.0-19.8)   20.2 (19.8-20.6)   21.3 (21.0-21.7)   23.3 (22.9-23.6)   \<.001
  Diabetes                                                           31.8 (31.6-31.9)                                                         30.6 (30.2-30.9)      31.3 (30.9-31.6)   31.7 (31.4-32.1)   32.4 (32.0-32.7)   32.6 (32.3-33.0)   \<.001
  Dyslipidemia                                                       20.8 (20.6-21.0)                                                         18.0 (17.7-18.4)      19.1 (18.7-19.5)   20.6 (20.2-21.0)   22.2 (21.8-22.6)   23.5 (23.0-23.9)   \<.001
  Hypertension                                                       46.5 (46.3-46.7)                                                         48.3 (47.9-48.8)      49.6 (49.2-50.1)   50.6 (50.1-51.1)   48.7 (48.3-49.1)   36.6 (36.3-36.9)   \<.001
  Obesity                                                            14.2 (14.0-14.3)                                                         11.8 (11.5-12.1)      12.9 (12.6-13.2)   14.2 (13.9-14.5)   15.3 (14.9-15.6)   16.3 (15.9-16.6)   \<.001
  Pneumonia                                                          14.2 (14.0-14.3)                                                         14.0 (13.7-14.2)      14.2 (13.9-14.5)   14.5 (14.2-14.7)   14.0 (13.8-14.3)   14.1 (13.9-14.3)   .76
  Stroke                                                             3.5 (3.4-3.5)                                                            3.3 (3.2-3.4)         3.3 (3.2-3.4)      3.5 (3.4-3.6)      3.5 (3.4-3.6)      3.6 (3.5-3.7)      \<.001

Trends in CLD-Related Hospitalizations {#H2-7-ZOI200103}
--------------------------------------

The annual rate of CLD-related hospitalizations per 100 000 hospitalizations increased from 3056 (95% CI, 3042-3069) in 2012 to 3757 (95% CI, 3742-3772) in 2016 (*P* for trend \< .001) ([Table 1](#zoi200103t1){ref-type="table"}). The total number of CLD-related hospitalizations increased by 20.8% (187 690 in 2012 to 226 714 in 2016). When stratified by age, while the proportion of hospitalizations for patients aged 45 to 64 years decreased (55.5% \[95% CI, 55.1%-55.9%\] in 2012 to 50.3% \[95% CI, 49.9%-50.6%\] in 2016; *P* for trend \< .001), the proportion for those aged 65 years or older showed a considerable increase (27.4% \[95% CI, 26.9%-27.9%\] in 2012 to 32.2% \[95% CI, 31.7%-32.6%\] in 2016; *P* for trend \< .001). Mean (SD) age increased (56.8 \[14.2\] years in 2012 to 57.8 \[14.6\] years in 2016; *P* for trend \< .001). There were also increases in the proportion of hospitalizations for patients enrolled in Medicare (41.7% \[95% CI, 41.1%-42.2%\] to 43.6% \[95% CI, 43.1%-44.1%\]; *P* for trend \< .001). The proportion enrolled in Medicaid also increased, while the proportion of uninsured (ie, self-pay) hospitalizations decreased ([Table 1](#zoi200103t1){ref-type="table"}). Among CLD etiologies, the proportion of hospitalizations with HBV and HCV decreased ([Table 1](#zoi200103t1){ref-type="table"}), while the proportion with alcoholic cirrhosis increased (19.4% \[95% CI, 19.1%-19.8%\] in 2012 to 37.7% \[95% CI, 37.2%-38.1%\] in 2016) (*P* for trend \< .001 for all). The proportion of hospitalizations with NAFLD increased from 18.6% (95% CI, 18.2%-19.0%) in 2012 to 21.4% (95% CI, 21.0%-21.8%) in 2015; however, it decreased to 18.0% (95% CI, 17.6%-18.4%) in 2016. The proportion of hospitalizations with cirrhosis and 1 or more concurrent complication showed substantial increases ([Table 1](#zoi200103t1){ref-type="table"}). The comorbidity burden among CLD-related hospitalizations showed a significant increase for all comorbid conditions analyzed.

In-Hospital Mortality Among CLD-Related Hospitalizations {#H2-8-ZOI200103}
--------------------------------------------------------

Among CLD-related hospitalizations, the crude in-hospital mortality rate remained stable from 7.4% (95% CI, 7.2%-7.6%) in 2012 to 7.3% (95% CI, 7.1%-7.4%) in 2016 (*P* for trend = .33) ([Table 2](#zoi200103t2){ref-type="table"}), while the overall adjusted in-hospital mortality rate showed a decrease (odds ratio, 0.96; 95% CI, 0.95-0.96; *P* for trend \< .001) (eTable 3 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}). The proportion of in-hospital deaths increased with increasing age ([Table 2](#zoi200103t2){ref-type="table"}). Despite lower proportions of Asian/Pacific Islander individuals among the total cohort, those with Asian/Pacific Islander or African American background had higher rates of in-hospital death compared with individuals of other races ([Table 2](#zoi200103t2){ref-type="table"}). Rates of in-hospital mortality were higher among CLD-related hospitalizations with Medicare compared with other insurance types ([Table 2](#zoi200103t2){ref-type="table"}). Among etiologies, hospitalizations with HBV and HCV had relatively low in-hospital mortality rates and showed small increases ([Table 2](#zoi200103t2){ref-type="table"}), while hospitalizations with alcoholic cirrhosis had the highest in-hospital mortality rate and showed the greatest increase (11.1% \[95% CI, 10.7%-11.5%\] in 2012 to 13.4% \[95% CI, 13.1%-13.7%\] in 2016, *P* for trend \< .001). The overall rate of alcoholic cirrhosis was 11.9% (95% CI, 11.7%-12.0%). The in-hospital mortality rate among hospitalizations of patients with cirrhosis increased significantly, and an increasing number of concurrent cirrhosis-related complications was associated with increasing in-hospital mortality rates ([Table 2](#zoi200103t2){ref-type="table"}). For example, the in-hospital mortality rate among patients with 2 or more cirrhosis-related complications was considerably higher than the rate among patients who had cirrhosis but no cirrhosis-related complications (13.1% \[95% CI, 12.9%-13.3%\] vs 4.8% \[95% CI, 4.7%-4.9%\]; *P* \< .001). Presence of hepatocellular carcinoma was also associated with a high mortality rate (9.8% \[95% CI, 9.5%-10.1%\]).

###### Trends in In-Hospital Mortality

  Characteristic                                       Proportion with in-hospital mortality, weighted % (95% CI)   *P* value for trend                                                                               
  ---------------------------------------------------- ------------------------------------------------------------ --------------------- ------------------ ------------------ ------------------ ------------------ --------
  Overall                                              7.4 (7.4-7.5)                                                7.4 (7.2-7.6)         7.5 (7.3-7.6)      7.6 (7.4-7.8)      7.4 (7.3-7.6)      7.3 (7.1-7.4)      .33
  Age, y                                                                                                                                                                                                              
  \<25                                                 2.6 (2.3-2.8)                                                2.7 (2.1-3.3)         2.2 (1.8-2.8)      2.5 (2.0-3.1)      2.6 (2.1-3.3)      2.8 (2.3-3.4)      .43
  25-44                                                3.7 (3.5-4.0)                                                3.6 (3.4-3.9)         3.9 (3.6-4.1)      3.8 (3.6-4.1)      3.5 (3.3-3.8)      3.7 (3.5-4.0)      .77
  45-64                                                6.5 (6.4-6.5)                                                6.4 (6.2-6.6)         6.5 (6.3-6.7)      6.5 (6.4-6.7)      6.5 (6.3-6.7)      6.4 (6.2-6.6)      .62
  ≥65                                                  11.4 (11.3-11.5)                                             11.7 (11.4-12.0)      11.6 (11.3-11.9)   11.9 (11.6-12.2)   11.3 (11.0-11.6)   10.7 (10.5-11.0)   \<.001
  Sex                                                                                                                                                                                                                 
  Male                                                 7.4 (7.4-7.5)                                                7.4 (7.2-7.6)         7.5 (7.3-7.7)      7.6 (7.4-7.8)      7.4 (7.2-7.6)      7.3 (7.1-7.5)      .39
  Female                                               7.4 (7.3-7.5)                                                7.4 (7.2-7.6)         7.5 (7.3-7.7)      7.6 (7.4-7.8)      7.5 (7.3-7.7)      7.3 (7.1-7.5)      .47
  Race                                                                                                                                                                                                                
  White                                                7.5 (7.4-7.6)                                                7.5 (7.3-7.7)         7.5 (7.3-7.7)      7.7 (7.5-7.9)      7.5 (7.3-7.7)      7.3 (7.1-7.5)      .23
  African American                                     7.7 (7.5-7.8)                                                7.4 (7.0-7.8)         7.5 (7.2-7.9)      7.8 (7.4-8.2)      8.0 (7.6-8.4)      7.7 (7.4-8.0)      .09
  Hispanic                                             6.3 (6.1-6.4)                                                6.4 (6.1-6.8)         6.5 (6.2-6.9)      6.4 (6.1-6.8)      6.0 (5.7-6.4)      6.0 (5.7-6.3)      .02
  Asian/Pacific Islander                               8.8 (8.4-9.2)                                                8.7 (7.8-9.6)         9.3 (8.4-10.2)     9.0 (8.2-9.9)      8.7 (7.9-9.5)      8.3 (7.6-9.1)      .25
  Insurance                                                                                                                                                                                                           
  Medicare                                             9.1 (9.0-9.2)                                                9.1 (8.8-9.3)         9.2 (8.9-9.4)      9.4 (9.1-9.6)      9.1 (8.9-9.4)      8.8 (8.6-9.0)      .12
  Medicaid                                             5.5 (5.4-5.6)                                                5.5 (5.3-5.8)         5.8 (5.5-6.1)      5.6 (5.3-5.8)      5.3 (5.0-5.5)      5.4 (5.2-5.6)      .05
  Private, including health maintenance organization   6.8 (6.7-6.9)                                                6.9 (6.6-7.2)         6.6 (6.4-6.9)      6.8 (6.5-7.1)      6.9 (6.6-7.1)      6.7 (6.4-7.0)      .77
  Self-pay                                             6.0 (5.8-6.2)                                                5.9 (5.5-6.3)         6.0 (5.6-6.5)      6.4 (5.9-6.9)      5.9 (5.5-6.4)      5.6 (5.2-6.1)      .46
  Alcoholic cirrhosis                                  11.9 (11.7-12.0)                                             11.1 (10.7-11.5)      10.7 (10.3-11.0)   10.7 (10.4-11.1)   11.8 (11.4-12.1)   13.4 (13.1-13.7)   \<.001
  Hepatitis B virus                                    4.4 (4.2-4.6)                                                4.3 (3.8-4.7)         4.2 (3.8-4.7)      4.5 (4.1-5.0)      4.4 (4.0-4.9)      4.4 (4.0-4.9)      .43
  Hepatitis C virus                                    4.1 (4.1-4.2)                                                3.9 (3.7-4.1)         4.2 (4.0-4.4)      4.2 (4.0-4.4)      4.3 (4.2-4.5)      4.0 (3.8-4.1)      .44
  Nonalcoholic fatty liver disease                     4.1 (4.0-4.3)                                                4.8 (4.5-5.0)         4.6 (4.4-4.9)      4.7 (4.5-4.9)      4.0 (3.8-4.2)      2.7 (2.5-2.9)      \<.001
  Hepatocellular carcinoma                             9.8 (9.5-10.1)                                               9.7 (9.0-10.4)        9.4 (8.6-10.1)     9.9 (9.2-10.6)     10.1 (9.4-10.8)    9.8 (9.2-10.5)     .37
  Cirrhosis                                            9.1 (9.0-9.2)                                                8.3 (8.1-8.5)         8.1 (7.9-8.4)      8.3 (8.1-8.5)      9.0 (8.8-9.2)      11.2 (10.9-11.4)   \<.001
  Cirrhosis-related complications                                                                                                                                                                                     
  0                                                    4.8 (4.7-4.9)                                                5.0 (4.7-5.3)         5.3 (5.0-5.5)      5.2 (4.9-5.5)      4.6 (4.4-4.9)      4.1 (3.9-4.3)      \<.001
  1                                                    9.6 (9.4-9.7)                                                8.0 (7.7-8.2)         7.6 (7.3-7.9)      7.9 (7.6-8.1)      9.6 (9.3-9.8)      13.6 (13.2-13.9)   \<.001
  ≥2                                                   13.1 (12.9-13.3)                                             13.2 (12.7-13.7)      12.8 (12.3-13.3)   12.8 (12.3-13.3)   12.9 (12.5-13.4)   13.7 (13.2-14.1)   .09
  Coronary artery disease                              9.4 (9.2-9.6)                                                9.2 (8.8-9.6)         9.4 (9.0-9.8)      9.7 (9.3-10.1)     9.2 (8.9-9.6)      9.4 (9.1-9.8)      .71
  Congestive heart failure                             12.8 (12.6-13.0)                                             12.8 (12.4-13.3)      13.5 (13.0-13.9)   13.3 (12.8-13.7)   12.7 (12.3-13.1)   12.1 (11.8-12.5)   \<.001
  Chronic kidney disease                               10.2 (10.1-10.4)                                             10.3 (10.0-10.7)      10.5 (10.2-10.9)   10.5 (10.2-10.9)   10.3 (10.0-10.6)   9.7 (9.5-10.0)     .002
  Diabetes                                             6.6 (6.5-6.7)                                                6.6 (6.4-6.8)         6.6 (6.3-6.8)      6.6 (6.4-6.9)      6.6 (6.4-6.8)      6.5 (6.3-6.7)      .31
  Dyslipidemia                                         6.5 (6.3-6.6)                                                6.3 (6.0-6.5)         6.3 (6.0-6.6)      6.7 (6.4-7.0)      6.5 (6.2-6.7)      6.5 (6.3-6.8)      .10
  Hypertension                                         6.6 (6.5-6.7)                                                6.8 (6.6-7.0)         6.8 (6.6-7.0)      7.0 (6.8-7.2)      6.7 (6.6-6.9)      5.6 (5.4-5.8)      \<.001
  Obesity                                              6.2 (6.0-6.3)                                                6.3 (5.9-6.6)         6.1 (5.7-6.4)      6.3 (6.0-6.7)      6.2 (5.9-6.5)      6.0 (5.8-6.3)      .46
  Pneumonia                                            15.2 (15.0-15.4)                                             15.1 (14.6-15.6)      15.3 (14.8-15.8)   15.7 (15.2-16.2)   15.2 (14.7-15.6)   14.8 (14.4-15.3)   .33
  Stroke                                               14.2 (13.8-14.6)                                             13.4 (12.6-14.3)      13.6 (12.7-14.5)   14.8 (13.9-15.7)   14.4 (13.6-15.3)   14.5 (13.7-15.2)   .04

Hospitalization Costs Among CLD-Related Hospitalizations {#H2-9-ZOI200103}
--------------------------------------------------------

The mean cost per CLD-related hospitalization was \$16 271 (95% CI, \$16 069-\$16 473), while the total national estimated cost for CLD-related hospitalizations over the study period was \$81.1 billion (95% CI, \$79.4 billion to \$82.7 billion). The adjusted mean cost per CLD-related hospitalization increased by 0.62% (95% CI, 0.07%-1.18%; *P* for trend = .03) over the study period (eTable 3 in the [Supplement](#note-ZOI200103-1-s){ref-type="supplementary-material"}). From 2012 to 2016, mean hospitalization costs increased from \$15 611 (95% CI, \$13 870-\$17 353) to \$17 478 (95% CI, \$15 653-\$19 304) (*P* for trend \< .001), and total hospitalization costs increased from \$14.9 billion (95% CI, \$13.9 billion to \$15.9 billion) in 2012 to \$18.8 billion (95% CI, \$17.6 billion to \$20.0 billion) in 2016 ([Table 3](#zoi200103t3){ref-type="table"}). While mean and total hospitalization costs increased for all age groups ([Table 3](#zoi200103t3){ref-type="table"} and [Figure 1](#zoi200103f1){ref-type="fig"}A), total costs were highest among hospitalized patients aged 45 to 64 years ([Figure 1](#zoi200103f1){ref-type="fig"}A). Mean hospitalization costs increased significantly among men and women; however, men had a higher total cost burden (\$47.6 billion \[95% CI, \$46.5 billion to \$48.6 billion\] vs \$33.5 billion \[95% CI, \$32.8 billion to \$34.2 billion\]) ([Figure 1](#zoi200103f1){ref-type="fig"}B). While African American individuals had the most significant increase in mean hospitalization costs, mean costs were highest among Asian/Pacific Islander individuals ([Table 3](#zoi200103t3){ref-type="table"}), and white patients had the highest total economic burden (\$48.5 billion \[95% CI, \$47.5 billion to \$49.6 billion\]) ([Figure 1](#zoi200103f1){ref-type="fig"}C).

###### Trends in Mean Hospitalization Costs

  Characteristic                                       Costs, weighted mean (95% CI), 2016 US dollars   *P* value for trend                                                                                 
  ---------------------------------------------------- ------------------------------------------------ ------------------------ ------------------------ ------------------------ ------------------------ --------
  Total costs (95% CI), 2016 US dollars, billions      14.9 (13.9-15.9)                                 15.2 (14.2-16.2)         16.1 (15.0-17.1)         16.1 (15.1-17.1)         18.8 (17.6-20.0)         
  Overall                                              16 168 (15 667-16 670)                           16 094 (15 618-16 571)   16 332 (15 821-16 843)   15 763 (15 324-16 203)   16 919 (16 417-17 422)   \<.001
  Age, y                                                                                                                                                                                                    
  \<25                                                 15 611 (13 870-17 353)                           15 731 (14 043-17 420)   16 958 (15 234-18 681)   16 823 (15 434-18 212)   17 478 (15 653-19 304)   \<.001
  25-44                                                14 607 (13 969-15 245)                           14 766 (14 136-15 397)   15 098 (14 482-15 714)   14 239 (13 702-14 777)   16 038 (15 371-16 704)   \<.001
  45-64                                                16 211 (15 656-16 765)                           16 009 (15 501-16 516)   16 389 (15 822-16 955)   15 842 (15 365-16 319)   17 071 (16 500-17 642)   \<.001
  ≥65                                                  17 013 (16 543-17 483)                           16 996 (16 509-17 483)   16 855 (16 398-17 313)   16 361 (15 944-16 779)   17 100 (16 674-17 527)   .01
  Sex                                                                                                                                                                                                       
  Male                                                 16 424 (15 883-16 966)                           16 458 (15 938-16 979)   16 738 (16 184-17 291)   16 180 (15 710-16 650)   17 426 (16 870-17 982)   \<.001
  Female                                               15 818 (15 335-16 302)                           15 601 (15 140-16 062)   15 789 (15 299-16 278)   15 212 (14 785-15 639)   16 247 (15 780-16 713)   \<.001
  Race                                                                                                                                                                                                      
  White                                                15 540 (15 031-16 050)                           15 475 (14 998-15 952)   15 710 (15 214-16 205)   15 079 (14 672-15 487)   15 994 (15 531-16 457)   \<.001
  African American                                     16 615 (16 046-17 185)                           16 494 (15 905-17 083)   16 923 (16 340-17 510)   16 873 (16 311-17 435)   18 036 (17 370-18 703)   \<.001
  Hispanic                                             16 391 (15 275-17 507)                           16 516 (15 387-17 646)   16 848 (15 848-17 849)   15 773 (14 899-16 647)   17 434 (16 427-18 442)   \<.001
  Asian/Pacific Islander                               21 278 (19 163-23 392)                           22 312 (20 711-23 913)   22 383 (20 374-24 391)   20 262 (18 984-21 540)   22 302 (20 516-24 088)   .01
  Insurance                                                                                                                                                                                                 
  Medicare                                             16 435 (15 953-16 916)                           16 384 (15 912-16 856)   16 391 (15 911-16 870)   15 976 (15 562-16 391)   16 945 (16 504-17 387)   \<.001
  Medicaid                                             15 660 (15 052-16 268)                           15 748 (15 215-16 281)   16 215 (15 673-16 757)   15 335 (14 868-15 803)   17 229 (16 631-17 826)   \<.001
  Private, including health maintenance organization   17 832 (16 982-18 681)                           17 558 (16 760-18 355)   17 615 (16 758-18 473)   16 934 (16 202-17 667)   17 726 (16 919-18 533)   
  Self-pay                                             12 728 (12 250-13 207)                           12 690 (12 215-13 165)   12 944 (12 487-13 400)   12 277 (11 821-12 732)   13 160 (12 442-13 878)   
  Alcoholic cirrhosis                                  17 787 (17 140-18 434)                           17 615 (16 963-18 266)   17 677 (16 977-18 376)   17 453 (16 877-18 028)   20 282 (19 560-21 004)   \<.001
  Hepatitis B virus                                    15 203 (14 429-15 977)                           15 454 (14 659-16 248)   16 029 (15 112-16 947)   15 533 (14 749-16 318)   16 970 (16 069-17 871)   \<.001
  Hepatitis C virus                                    13 991 (13 502-14 479)                           14 164 (13 669-14 659)   14 290 (13 810-14 770)   14 197 (13 758-14 636)   15 085 (14 602-15 568)   \<.001
  Nonalcoholic fatty liver disease                     13 566 (13 119-14 013)                           13 346 (12 924-13 769)   13 456 (13 021-13 891)   13 203 (12 847-13 560)   13 769 (13 387-14 151)   \<.001
  Hepatocellular carcinoma                             18 512 (17 162-19 863)                           18 111 (16 528-19 694)   17 861 (16 579-19 143)   18 049 (16 718-19 380)   18 952 (17 563-20 341)   .14
  Cirrhosis                                            16 285 (15 663-16 908)                           16 190 (15 573-16 806)   16 309 (15 641-16 976)   16 298 (15 726-16 870)   19 185 (18 485-19 885)   \<.001
  Cirrhosis-related complications                                                                                                                                                                           
  0                                                    13 313 (12 868-13 759)                           13 402 (12 950-13 855)   13 390 (12 950-13 829)   13 165 (12 803-13 528)   13 616 (13 246-13 985)   \<.001
  1                                                    15 303 (14 775-15 831)                           15 170 (14 652-15 689)   15 169 (14 673-15 666)   15 747 (15 280-16 213)   20 041 (19 415-20 667)   \<.001
  ≥2                                                   22 185 (20 858-23 512)                           21 759 (20 530-22 988)   21 958 (20 418-23 498)   21 027 (19 821-22 233)   23 279 (21 718-24 841)   .20
  Coronary artery disease                              17 096 (16 531-17 660)                           16 699 (16 150-17 249)   17 297 (16 714-17 880)   16 627 (16 195-17 059)   17 712 (17 194-18 230)   \<.001
  Congestive heart failure                             23 012 (22 073-23 951)                           21 906 (21 118-22 695)   22 530 (21 704-23 356)   21 292 (20 600-21 984)   22 489 (21 715-23 263)   .20
  Chronic kidney disease                               19 803 (18 940-20 667)                           19 228 (18 526-19 929)   19 517 (18 742-20 291)   18 562 (17 960-19 164)   20 049 (19 274-20 823)   .01
  Diabetes                                             15 800 (15 321-16 279)                           15 464 (15 028-15 900)   15 553 (15 093-16 014)   15 373 (14 958-15 788)   16 213 (15 769-16 657)   \<.001
  Dyslipidemia                                         15 094 (14 636-15 553)                           14 994 (14 614-15 374)   15 373 (14 949-15 797)   14 962 (14 618-15 306)   15 787 (15 386-16 186)   \<.001
  Hypertension                                         15 930 (15 448-16 413)                           15 529 (15 107-15 951)   15 843 (15 394-16 292)   15 209 (14 839-15 579)   14 913 (14 527-15 299)   .56
  Obesity                                              17 692 (17 096-18 287)                           17 318 (16 750-17 887)   17 471 (16 909-18 032)   17 200 (16 685-17 714)   18 162 (17 591-18 734)   .01
  Pneumonia                                            27 959 (26 718-29 200)                           27 066 (25 973-28 160)   27 815 (26 694-28 936)   25 710 (24 768-26 653)   28 360 (27 217-29 503)   .17
  Stroke                                               25 569 (24 115-27 024)                           24 944 (23 507-26 381)   25 885 (24 499-27 272)   24 571 (23 348-25 794)   28 509 (26 978-30 039)   \<.001

![Trends in Total Hospitalization Costs Stratified by Demographic Characteristics\
Costs are shown in 2016 US dollars. Error bars represent 95% CIs; HMO, health maintenance organization.](jamanetwopen-3-e201997-g001){#zoi200103f1}

Compared with other insurance types, hospitalizations of patients with private insurance had higher mean costs ([Table 3](#zoi200103t3){ref-type="table"}), hospitalizations of those enrolled in Medicare had a higher total burden ([Figure 1](#zoi200103f1){ref-type="fig"}D), and mean costs for hospitalizations of patients enrolled in Medicaid experienced the greatest increase (\$15 660 \[95% CI, \$15 052-\$16 268\] in 2012 to \$17 229 \[95% CI, \$16 631-\$17 826\] in 2016; *P* for trend \< .001). Cost burden increased across all etiologies, with a higher total cost burden among hospitalizations with alcoholic cirrhosis (\$22.7 billion \[95% CI, \$22.1 billion to \$23.2 billion\]) or hepatitis C virus (\$22.6 billion \[95% CI, \$22.1 billion to \$23.2 billion\]) ([Table 3](#zoi200103t3){ref-type="table"} and [Figure 2](#zoi200103f2){ref-type="fig"}A). Mean costs per hospitalization were higher among patients with alcoholic cirrhosis and HBV compared with the other etiologies. Hospitalizations for patients with HCV had the highest total costs from 2012 to 2015, and those with alcoholic cirrhosis had the highest total costs in 2016 ([Figure 2](#zoi200103f2){ref-type="fig"}A). Hospitalization costs increased among patients with cirrhosis, with a higher burden among patients with concurrent cirrhosis-related complications ([Table 3](#zoi200103t3){ref-type="table"} and [Figure 2](#zoi200103f2){ref-type="fig"}B). While CLD-related hospitalizations with concurrent congestive heart failure, pneumonia, or stroke had relatively higher mean costs, hospitalizations with concurrent diabetes and hypertension had a higher total cost burden compared with other comorbidities ([Figure 2](#zoi200103f2){ref-type="fig"}C).

![Trends in Total Hospitalization Costs Stratified by Clinical Characteristics\
Costs are shown in 2016 US dollars. CAD indicates coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; and error bars, 95% CIs.](jamanetwopen-3-e201997-g002){#zoi200103f2}

Discussion {#H1-4-ZOI200103}
==========

Among a large, nationally representative sample of hospitalized US adults from 2012 to 2016, there was a 20.8% increase in the number of CLD-related hospitalizations, resulting in a 26.2% increase in the total estimated hospitalization costs. In 2016, CLD-related hospitalizations alone accounted for \$18.8 billion of the economic burden.

The observed increases in the clinical and economic burden of CLD among hospitalized adults in the US is a major public health concern. Improvements in the management of viral hepatitis, specifically the introduction of direct-acting antivirals for HCV treatment,^[@zoi200103r29]^ have led to significantly reduced morbidity and mortality associated with HBV and HCV.^[@zoi200103r30],[@zoi200103r31],[@zoi200103r32],[@zoi200103r33],[@zoi200103r34],[@zoi200103r35],[@zoi200103r36]^ However, existing studies^[@zoi200103r4],[@zoi200103r11]^ highlight the growing epidemic of NAFLD in the US. Studies^[@zoi200103r2],[@zoi200103r5],[@zoi200103r6]^ have also shown the rising prevalence of ALD and increasing disease severity among patients with ALD, with consistent trends across different nationally representative databases. In this study, while the proportion of patients with alcoholic cirrhosis and NAFLD showed an increasing trend, the highest mortality burden was among hospitalizations with alcoholic cirrhosis, and the major cost burden was distributed between hospitalizations of patients with alcoholic cirrhosis and HCV. Even with decreasing HCV-associated morbidity and mortality, the high HCV cost burden may be due to aging patients with HCV cirrhosis and continued suboptimal access to HCV treatment.^[@zoi200103r37],[@zoi200103r38]^

These epidemiological trends likely reflect the lack of early diagnosis, of ALD and NAFLD in particular, and the paucity of effective therapies to treat and prevent disease progression. The findings of the current study raise concern regarding the vast burden of CLD on the US health care system, and the impending wave of patients with ALD and NAFLD will further stress the health care system unless precautionary actions are taken. There is an urgent need for greater awareness among patients and clinicians about the consequences of unhealthy alcohol use, the need for consistent screening for alcohol use disorder, and timely implementation of prevention and intervention strategies aimed specifically at addressing alcohol use disorders.

In this study, presence of cirrhosis and cirrhosis-related complications resulted in a higher mortality rate and cost burden on the health care system. Tapper et al^[@zoi200103r39]^ applied a quality improvement intervention on an inpatient liver unit that resulted in a 40% reduction in 30-day readmissions among patients with cirrhosis, which was likely driven by a decrease in readmissions for hepatic encephalopathy. Kanwal et al^[@zoi200103r40]^ demonstrated that while early clinic follow-up following hospital discharge led to an increase in readmissions, this ultimately translated into reduced overall mortality. Similarly, other studies have proposed quality improvement tools and shown that prevention and early management of cirrhosis are cost-effective.^[@zoi200103r41],[@zoi200103r42],[@zoi200103r43],[@zoi200103r44],[@zoi200103r45],[@zoi200103r46]^ However, owing to the lack of nationally representative data to guide the optimal allocation of resources and preventive efforts, there is a lag in the application and use of these evidence-based protocols by clinicians.

With advancements in medical care, there is a shift in the burden toward an older population. This is reflected in the current study, which observed increases in the mean age of hospitalized patients with CLD and found that 42.7% of hospitalizations were for patients enrolled in Medicare. This is particularly concerning given that older populations have higher risk of comorbidities. A recent study by Younossi et al^[@zoi200103r4]^ showed that increases in the prevalence of NAFLD were associated with increasing rates of obesity and type 2 diabetes.^[@zoi200103r47],[@zoi200103r48],[@zoi200103r49]^ This study demonstrated similar observations showing concurrent increases in the comorbidity burden, albeit among a hospitalized cohort. As with prior studies, the presence of these comorbidities was associated with worse prognosis among this CLD cohort.^[@zoi200103r6],[@zoi200103r50],[@zoi200103r51]^

The proportion of CLD-related hospitalizations for patients enrolled in Medicare increased significantly over the study period, and hospitalizations for those with Medicare experienced the highest in-hospital mortality rate as well as the greatest total economic burden. Asrani et al^[@zoi200103r14]^ found a similar trend among hospitalizations covered by Medicare (increase from 31.8% to 41.5%). These observations, along with the results of the current study, draw attention to the imminent surge in the burden of older patients with CLD and call attention to the need for greater research aimed at preventive care and novel quality-driven health care delivery so that we may adequately address the future needs of patients with CLD in a cost-effective and cost-efficient manner.

Limitations {#H2-10-ZOI200103}
-----------

As with many studies using large claims databases, these findings should be interpreted within the context of certain limitations.^[@zoi200103r52]^ The NIS records data per hospitalization, and not per individual patient, without linkage or follow-up data. Owing to the cross-sectional nature of the database, longitudinal analysis is not possible, and no causal inferences can be drawn. Thus, there may be repeat hospitalizations of patients with CLD among this study cohort. Nevertheless, given that the main objective of this study was to characterize the overall clinical and economic burden of CLD hospitalizations in the US, these results still provide critical data to address this important public health concern. This study focused specifically on alcoholic cirrhosis to minimize error in the estimates given the limitations inherent in the use of *ICD-9-CM* coding-based algorithms to identify and isolate ALD as a whole. However, because this study focused specifically on alcoholic cirrhosis, it may not capture the true burden of ALD (eg, the burden among patients with alcoholic hepatitis who may be hospitalized but do not have cirrhosis). A considerable proportion of hospitalizations did not have an identifiable underlying etiology. Hospitalizations in this category related to CLD may be attributable to other chronic diseases (eg, cholestatic liver diseases). The changes in coding and data structure of the NIS in 2015 may have resulted in misclassification bias,^[@zoi200103r21]^ and the *P* value for trend for some characteristics may not be as informative owing to these changes. Chronic liver disease with mention of alcohol is more thoroughly defined in *ICD-10-CM* (K70.xx) compared with the *ICD-9-CM*; however, NAFLD *ICD* codes still lack specificity in both coding systems. This change may have contributed to the apparent increased burden of alcoholic cirrhosis and decreased burden of NAFLD in 2016. The loss of Elixhauser comorbidity software within the NIS for the fourth quarter of 2015 and for 2016 may have led to underestimation of the burden of certain comorbidities (eg, hypertension). We tried to circumvent these limitations through a comprehensive review of *ICD* codes to ensure that our definitions using *ICD-10-CM* codes are congruent with the *ICD-9-CM* codes previously used.

Conclusions {#H1-5-ZOI200103}
===========

While this study is unable to account for outpatient outcomes, including mortality following hospitalization and long-term costs associated with chronic care, inpatient burden is a common and relevant metric used to estimate the health care burden for chronic conditions. Similar to other chronic diseases, a large proportion of CLD-related health care burden is reflected in inpatient mortality and resource utilization. In addition, severe decompensation often leads to hospitalization, which has been linked to early mortality among patients with other chronic conditions.^[@zoi200103r46],[@zoi200103r53],[@zoi200103r54],[@zoi200103r55]^ Thus, despite inherent limitations and potential underestimation of the true burden of CLD, this study provides a comprehensive view of trends in CLD-related inpatient resource utilization in the US as a stepping stone to guide health care policy and more efficient allocation of resources to address the looming burden of an aging CLD population with higher morbidity and mortality.
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